Several limitations associated with the present study
warrant mention. First, the accumulated data were obtained from retrospective studies with a moderate quality,
which might have caused some bias. Second, we attempted
to establish two definitions of malignant transformation.
This might have been inappropriate in some cases, as the
histological diagnosis rate for recurrences might differ
among institutes, and some institutes employed various
MRI sequences or positron emission tomography for the
Neurol Med Chir (Tokyo) 62, April, 2022
1) Louis DN, Ohagaki H, Wiestler OD, et al.: WHO classification of
tumours of the central nervous system, International Agency for
Research on Cancer, Lyon, 2016
2) Louis DN, Perry A, Wesseling P, et al.: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary.
Neuro Oncol 23: 1231-1251, 2021
3) Nakasu S, Notsu A, Nakasu Y: Prevalence of incidental meningiomas and gliomas on MRI: A meta-analysis and metaregression analysis. Acta Neurochir (Wien) 163: 3401-3415, 2021
184
S. Nakasu et al.
4) Jansen E, Hamisch C, Ruess D, et al.: Observation after surgery
for low grade glioma: Long-term outcome in the light of the
2016 WHO classification. J Neurooncol 145: 501-507, 2019
5) Thon N, Eigenbrod S, Kreth S, et al.: IDH1 mutations in grade II
astrocytomas are associated with unfavorable progression-free
survival and prolonged postrecurrence survival. Cancer 118: 452460, 2012
6) Lima GL, Zanello M, Mandonnet E, Taillandier L, Pallud J,
Duffau H: Incidental diffuse low-grade gliomas: From early detection to preventive neuro-oncological surgery. Neurosurg Rev 39:
377-384, 2016
7) Duffau H: Long-term outcomes after supratotal resection of diffuse low-grade gliomas: A consecutive series with 11-year followup. Acta Neurochir (Wien) 158: 51-58, 2016
8) Narang AK, Chaichana KL, Weingart JD, et al.: Progressive lowgrade glioma: Assessment of prognostic importance of histologic
reassessment and MRI findings. World Neurosurg 99: 751-757,
2017
9) Capelle L, Fontaine D, Mandonnet E, et al.: Spontaneous and
therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: A series of 1097 cases:
Clinical article. J Neurosurg 118: 1157-1168, 2013
10) Obara T, Blonski M, Brzenczek C, et al.: Adult diffuse low-grade
gliomas: 35-year experience at the nancy france neurooncology
unit. Front Oncol 10: 2020
11) Tom M, Park D, Wei W, et al.: Malignant transformation of adult
low grade glioma: Risk factors and outcomes in the molecular
era. Int J Radiat Oncol Biol Phys 105: S143, 2019
12) Cesselli D, Ius T, Isola M, et al.: Application of an artificial intelligence algorithm to prognostically stratify grade II gliomas. Cancers 12: 50, 2021
13) Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical
methods for incorporating summary time-to-event data into
meta-analysis. Trials 8: 16, 2007
14) Aoki K, Suzuki H, Yamamoto T, et al.: Mathematical modeling
and mutational analysis reveal optimal therapy to prevent malignant transformation in grade II IDH-mutant gliomas. Cancer Res
81: 4861-4873, 2021
15) Ahmadi R, Dictus C, Hartmann C, et al.: Long-term outcome and
survival of surgically treated supratentorial low-grade glioma in
adult patients. Acta Neurochir (Wien) 151: 1359-1365, 2009
16) Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D:
Adult supratentorial low-grade glioma: Long-term experience at
a single institution. Int J Radiat Oncol Biol Phys 75: 1401-1407,
2009
17) Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J, Hansen S:
A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). J Neurooncol 114: 309-317, 2013
18) El-Hateer H, Souhami L, Roberge D, et al.: Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article. J
Neurosurg 111: 265-271, 2009
19) Etxaniz O, Carrato C, de Aguirre I, et al.: IDH mutation status
trumps the Pignatti risk score as a prognostic marker in lowgrade gliomas. J Neurooncol 135: 273-284, 2017
20) Gousias K, Schramm J, Simon M: Extent of resection and survival in supratentorial infiltrative low-grade gliomas: Analysis of
and adjustment for treatment bias. Acta Neurochir (Wien) 156:
327-337, 2014
21) Heo YJ, Park JE, Kim HS, et al.: Prognostic relevance of gemistocytic grade II astrocytoma: Gemistocytic component and MR imaging features compared to non-gemistocytic grade II astrocytoma. Eur Radiol 27: 3022-3032, 2017
22) Iwadate Y, Matsutani T, Hirono S, Ikegami S, Shinozaki N, Saeki
N: IDH1 mutation is prognostic for diffuse astrocytoma but not
low-grade oligodendrogliomas in patients not treated with early
radiotherapy. J Neurooncol 124: 493-500, 2015
23) Jaber M, Ewelt C, Wölfer J, et al.: Is visible aminolevulinic acidinduced fluorescence an independent biomarker for prognosis in
histologically confirmed (World Health Organization 2016) lowgrade gliomas? Neurosurgery 84: 1214-1224, 2019
24) Jung TY, Jung S, Moon JH, et al.: Early prognostic factors related
to progression and malignant transformation of low-grade
gliomas. Clin Neurol Neurosurg 113: 752-757, 2011
25) Juratli TA, Kirsch M, Robel K, et al.: IDH mutations as an early
and consistent marker in low-grade astrocytomas WHO grade II
and their consecutive secondary high-grade gliomas. J Neurooncol
108: 403-410, 2012
26) Karschnia P, Teske N, Dorostkar MM, et al.: Extent and prognostic value of MGMT promotor methylation in glioma WHO grade
II. Sci Rep 10: 19758, 2020
27) Kavouridis VK, Boaro A, Dorr J, et al.: Contemporary assessment
of extent of resection in molecularly defined categories of diffuse
low-grade glioma: A volumetric analysis. J Neurosurg 133: 12911301, 2019
28) Koo T, Lim DH, Seol HJ, et al.: Impact of adjuvant treatments on
survival in Korean patients with WHO grade II gliomas: KNOG
15-02 and KROG 16-04 intergroup study. J Neurooncol 140: 445455, 2018
29) Leu S, von Felten S, Frank S, Boulay JL, Mariani L: IDH mutation
is associated with higher risk of malignant transformation in
low-grade glioma. J Neurooncol 127: 363-372, 2016
30) Majchrzak K, Kaspera W, Bobek-Billewicz B, et al.: The assessment of prognostic factors in surgical treatment of low-grade
gliomas: A prospective study. Clin Neurol Neurosurg 114: 11351144, 2012
31) Snyder LA, Wolf AB, Oppenlander ME, et al.: The impact of extent of resection on malignant transformation of pure oligodendrogliomas. J Neurosurg 120: 309-314, 2014
32) Suzuki A, Maruyama T, Nitta M, et al.: Evaluation of DNA ploidy
with intraoperative flow cytometry may predict long-term survival of patients with supratentorial low-grade gliomas: Analysis
of 102 cases. Clin Neurol Neurosurg 168: 46-53, 2018
33) Tanaka K, Sasayama T, Mizukawa K, et al.: Combined IDH1 mutation and MGMT methylation status on long-term survival of
patients with cerebral low-grade glioma. Clin Neurol Neurosurg
138: 37-44, 2015
34) Turkoglu E, Gurer B, Sanli AM, et al.: Clinical outcome of surgically treated low-grade gliomas: A retrospective analysis of a single institute. Clin Neurol Neurosurg 115: 2508-2513, 2013
35) Youland RS, Brown PD, Giannini C, Parney IF, Uhm JH, Laack
NN: Adult low-grade glioma: 19-year experience at a single institution. Am J Clin Oncol 36: 612-619, 2013
36) Zhang S, Chiang GC, Magge RS, et al.: Texture analysis on conventional MRI images accurately predicts early malignant transformation of low-grade gliomas. Eur Radiol 29: 2751-2759, 2019
37) Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa
A: Recurrence and malignant degeneration after resection of
adult hemispheric low-grade gliomas. J Neurosurg 112: 10-17,
2010
38) Eseonu CI, Eguia F, ReFaey K, et al.: Comparative volumetric
analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival. J
Neurooncol 134: 65-74, 2017
39) Fukuya Y, Ikuta S, Maruyama T, et al.: Tumor recurrence pat-
Neurol Med Chir (Tokyo) 62, April, 2022
Malignant Progression of Low-grade Gliomas
40)
41)
42)
43)
44)
45)
46)
47)
48)
terns after surgical resection of intracranial low-grade gliomas. J
Neurooncol 144: 519-528, 2019
Jakola AS, Myrmel KS, Kloster R, et al.: Comparison of a strategy
favoring early surgical resection vs a strategy favoring watchful
waiting in low-grade gliomas. JAMA 308: 1881-1888, 2012
Jungk C, Scherer M, Mock A, et al.: Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas
stratified for IDH1 mutation status: A single-center volumetric
analysis. J Neurooncol 129: 319-328, 2016
Ross DA, Tao S, Gultekin S, Ross AM: Lobar distribution of low
grade oligodendroglioma: Distribution, molecular characteristics,
and survival based upon location. J Cancer Ther 5: 1249, 2014
Jansen NL, Suchorska B, Wenter V, et al.: Dynamic 18F-FET PET
in newly diagnosed astrocytic low-grade glioma identifies highrisk patients. J Nucl Med 55: 198-203, 2014
Patel T, Bander ED, Venn RA, et al.: The role of extent of resection in IDH1 wild-type or mutant low-grade gliomas. Neurosurgery 82: 808-814, 2018
Sakarunchai I, Sangthong R, Phuenpathom N, Phukaoloun M:
Free survival time of recurrence and malignant transformation
and associated factors in patients with supratentorial low-grade
gliomas. J Med Assoc Thai 96: 1542-1549, 2013
Smith JS, Chang EF, Lamborn KR, et al.: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.
J Clin Oncol 26: 1338-1345, 2008
Gozé C, Blonski M, Le Maistre G, et al.: Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for
diffuse low-grade gliomas. Neuro Oncol 16: 1100-1109, 2014
Murphy ES, Leyrer CM, Parsons M, et al.: Risk factors for malignant transformation of low-grade glioma. Int J Radiat Oncol Biol
Neurol Med Chir (Tokyo) 62, April, 2022
185
Phys 100: 965-971, 2018
49) Pallud J, Blonski M, Mandonnet E, et al.: Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse lowgrade gliomas. Neuro Oncol 15: 595-606, 2013
50) Weller J, Katzendobler S, Karschnia P, et al.: PCV chemotherapy
alone for WHO grade 2 oligodendroglioma: Prolonged disease
control with low risk of malignant progression. J Neurooncol 2021
51) Wen B, Fu F, Hu L, et al.: Subventricular zone predicts high velocity of tumor expansion and poor clinical outcome in patients
with low grade astrocytoma. Clin Neurol Neurosurg 168: 12-17,
2018
52) Zeng L, Mei Q, Li H, Ke C, Yu J, Chen J: A survival analysis of
surgically treated incidental low-grade glioma patients. Sci Rep
11: 8522, 2021
53) Johnson BE, Mazor T, Hong C, et al.: Mutational analysis reveals
the origin and therapy-driven evolution of recurrent glioma. Science 343: 189-193, 2014
54) Yu Y, Villanueva-Meyer J, Grimmer MR, et al.: Temozolomideinduced hypermutation is associated with distant recurrence and
reduced survival after high-grade transformation of low-grade
IDH-mutant gliomas. Neuro Oncol 23: 1872-1884, 2021
55) Aihara K, Mukasa A, Nagae G, et al.: Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathol
Commun 5: 18, 2017
Corresponding author: Satoshi Nakasu, M.D.
Division of Neurosurgery, Omi Medical Center, 1660 Yabase-cho,
Kusatsu, Shiga 525-8585, Japan.
e-mail: neuro-nakasu@kfx.biglobe.ne.jp
...
論文の公開元へ
